Indivior (INDV) Reaches New 1-Year Low at $215.00

Indivior PLC (LON:INDV) shares hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 215 ($2.80) and last traded at GBX 215 ($2.80), with a volume of 4565887 shares changing hands. The stock had previously closed at GBX 257.40 ($3.35).

A number of research analysts have weighed in on INDV shares. Jefferies Financial Group reiterated a “buy” rating on shares of Indivior in a report on Wednesday, July 25th. Royal Bank of Canada reiterated an “outperform” rating and set a GBX 550 ($7.16) target price (up previously from GBX 540 ($7.03)) on shares of Indivior in a report on Friday, June 15th. Citigroup reduced their target price on Indivior from GBX 500 ($6.51) to GBX 365 ($4.75) and set a “neutral” rating on the stock in a report on Tuesday, July 17th. Numis Securities downgraded Indivior to a “hold” rating in a report on Wednesday, July 11th. Finally, Morgan Stanley reduced their target price on Indivior from GBX 455 ($5.93) to GBX 398 ($5.18) and set an “equal weight” rating on the stock in a report on Tuesday, June 19th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Indivior has a consensus rating of “Buy” and a consensus target price of GBX 444.60 ($5.79).

About Indivior (LON:INDV)

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Featured Article: Outstanding Shares and The Effect on Share Price

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply